As a prerequisite for the clinical development of immunotherapeutic strategies, we recently examined NPM-ALK-specific CD8 T cell responses in NPM-ALK-positive ALCL patients in remission after chemotherapy [60]. The gene discussed is CD8A; the disease is anaplastic large cell lymphoma.